Australian recommendations for the management of hepatitis C virus infection: A consensus statement

Medical Journal of Australia

Volumn 204, Issue 7, 2016, Pages 268-272

  Thompson, Alexander J V ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; DASABUVIR; LEDIPASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON ALPHA; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT;

ANEMIA; ANXIETY DISORDER; ARTICLE; AUSTRALIAN; BONE DENSITOMETRY; CHRONIC COUGH; CONSENSUS DEVELOPMENT; DISEASE TRANSMISSION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; GLOMERULUS FILTRATION RATE; HEADACHE; HEPATITIS C; HUMAN; INSOMNIA; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; NAUSEA; POLYMERASE CHAIN REACTION; PRURITUS; RASH; SALVAGE THERAPY; SEQUENCE ANALYSIS; THROMBOCYTE COUNT; ADOLESCENT; AUSTRALIA; BREAST FEEDING; CONSENSUS; DRUG INTERACTION; FEMALE; FOLLOW UP; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MALE; PHYSIOLOGIC MONITORING; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

ADOLESCENT; ANTIVIRAL AGENTS; AUSTRALIA; BREAST FEEDING; CONSENSUS; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; MALE; MONITORING, PHYSIOLOGIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84971617679     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja16.00106     Document Type: Article

References (29)

1. Sievert W, Razavi H, Estes C, et al. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. J Gastroenterol Hepatol 2014; 29 Suppl 1: 1-9.
2. Bowden DS, Berzsenyi MD. Chronic hepatitis C virus infection: genotyping and its clinical role. Future Microbiol 2006; 1: 103-112.
3. National Health and Medical Research Council. Australian guidelines to reduce health risks from drinking alcohol. Canberra: NHMRC, 2009. http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/ds10-alcohol.pdf (accessed Feb 2016).
4. Afdhal N, Reddy KR, Nelson DR, et al; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493.
5. Afdhal N, Zeuzem S, Kwo P, et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898.
6. Kemp W, Levy M, Weltman M, Lubel J. Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis. J Gastroenterol Hepatol 2015; 30: 453-462.
7. Gastrointestinal Expert Group. Advanced liver disease. In: Therapeutic guidelines: gastrointestinal. Version 6. Melbourne: Therapeutic Guidelines Limited, 2016.
8. Kowdley KV, Gordon SC, Reddy KR, et al; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888.
9. Wyles DL, Ruane PJ, Sulkowski MS, et al; ALLY-2 Investigators. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 714-725.
10. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221.
11. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-1603.
12. Ferenci P, Bernstein D, Lalezari J, et al; PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-1992.
13. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-1982.
14. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-1614.
15. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatmentexperienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147: 359-365.e1.
16. Jacobson IM, Gordon SC, Kowdley KV, et al; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877.
17. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887.
18. Zeuzem S, Dusheiko GM, Salupere R, et al; VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
19. Foster GR, Pianko S, Brown A, et al; BOSON Study Group. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015; 149: 1462-1470.
20. Foster GR, Pianko S, Cooper C, et al. Sofosbuvir þ peginterferon/ribavirin for 12 weeks vs sofosbuvir þ ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON Study [abstract L05]. J Hepatol 2015; 62 Suppl 2: S259-S260.
21. Nelson DR, Cooper JN, Lalezari JP, et al; ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127-1135.
22. Hézode C, De Ledinghen V, Fontaine H, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program. 66th Annual Meeting of the American Association for the Study of Liver Diseases; 2015 November 13e17; San Francisco, Calif.
23. Leroy V, Angus P, Bronowicki JP, et al. All-oral treatment with daclatasvir plus sofosbuvir plus ribavirin for 12 or 16 weeks in HCV genotype 3-infected patients with advanced fibrosis or cirrhosis: the ALLY-3þ Phase 3 Study. 66th Annual Meeting of the American Association for the Study of Liver Diseases; 2015 November 13e17; San Francisco, Calif.
24. Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 2015; 63: 581-585.
25. Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015; 62: 1040-1046.
26. Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis 2015; 15: 1049-1054.
27. Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 2015; 149: 1454-1461.e1.
28. Hezode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015; 385: 2502-2509.
29. Hezode C, Fontaine H, Dorival C, et al; CUPIC Study Group. Triple therapy in treatment-experienced patients with HCVcirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59: 434-441.